CN101535480A - 诊断方法和标记物 - Google Patents

诊断方法和标记物 Download PDF

Info

Publication number
CN101535480A
CN101535480A CNA2007800294658A CN200780029465A CN101535480A CN 101535480 A CN101535480 A CN 101535480A CN A2007800294658 A CNA2007800294658 A CN A2007800294658A CN 200780029465 A CN200780029465 A CN 200780029465A CN 101535480 A CN101535480 A CN 101535480A
Authority
CN
China
Prior art keywords
nucleic acid
seq
acid molecule
polypeptide
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800294658A
Other languages
English (en)
Chinese (zh)
Inventor
斯蒂芬·J·阿辛德
乔-安·斯坦顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otago Innovation Ltd
Original Assignee
Otago Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otago Innovation Ltd filed Critical Otago Innovation Ltd
Publication of CN101535480A publication Critical patent/CN101535480A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57434Specifically defined cancers of prostate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
CNA2007800294658A 2006-06-07 2007-06-07 诊断方法和标记物 Pending CN101535480A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81140706P 2006-06-07 2006-06-07
US60/811,407 2006-06-07

Publications (1)

Publication Number Publication Date
CN101535480A true CN101535480A (zh) 2009-09-16

Family

ID=38801699

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800294658A Pending CN101535480A (zh) 2006-06-07 2007-06-07 诊断方法和标记物

Country Status (8)

Country Link
US (1) US20110287010A1 (enExample)
EP (1) EP2029745B1 (enExample)
JP (1) JP2009539370A (enExample)
CN (1) CN101535480A (enExample)
AT (1) ATE528411T1 (enExample)
AU (1) AU2007255981A1 (enExample)
CA (1) CA2687997A1 (enExample)
WO (1) WO2007142540A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104878077A (zh) * 2014-02-28 2015-09-02 谭巍 PCA3 mRNA/ACPP mRNA RT-PCR检测引物及检测试剂盒

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2864794A4 (en) * 2012-06-20 2016-03-02 Merrimack Pharmaceuticals Inc MARKER QUANTIFICATION IN INDIVIDUAL CELLS IN TISSUE CUTS
KR101694226B1 (ko) 2012-06-29 2017-01-09 야마하하쓰도키 가부시키가이샤 피더와 피더 제어 방법 및 전자 부품 장착 장치
US9845472B2 (en) 2015-11-05 2017-12-19 Research Foundation Of The City University Of New York Methods of using PVT1 exon 9 to diagnose and treat prostate cancer
JP6307123B2 (ja) * 2016-08-02 2018-04-04 ヤマハ発動機株式会社 フィーダ及びフィーダ制御方法
EP4218784A3 (en) * 2017-05-22 2023-09-13 National Hellenic Research Foundation Macrocyclic modulators of disease associated protein misfolding and aggregation
US11225666B2 (en) 2018-03-16 2022-01-18 Research Foundation Of The City University Of New York Plasmid vector for expressing a PVT1 exon and method for constructing standard curve therefor

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5310687A (en) 1984-10-31 1994-05-10 Igen, Inc. Luminescent metal chelate labels and means for detection
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5082670A (en) 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US5028535A (en) 1989-01-10 1991-07-02 Biosite Diagnostics, Inc. Threshold ligand-receptor assay
US5939272A (en) 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5922615A (en) 1990-03-12 1999-07-13 Biosite Diagnostics Incorporated Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
WO1992005282A1 (en) 1990-09-14 1992-04-02 Biosite Diagnostics, Inc. Antibodies to complexes of ligand receptors and ligands and their utility in ligand-receptor assays
US5221685A (en) 1991-02-01 1993-06-22 Ube Industries, Ltd. Thiazoline derivative, process for preparing the same and chemical for controlling noxious organisms containing the same
CA2107899A1 (en) 1991-04-10 1992-10-11 Gunars Edwin Valkirs Novel conjugates and assays for simultaneous detection of multiple ligands
FI934437L (fi) 1991-04-10 1993-11-22 Biosite Diagnostics Inc Crosstalk-inhibitorer och deras anvaendning
US6019944A (en) 1992-05-21 2000-02-01 Biosite Diagnostics, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US6143576A (en) 1992-05-21 2000-11-07 Biosite Diagnostics, Inc. Non-porous diagnostic devices for the controlled movement of reagents
US5494829A (en) 1992-07-31 1996-02-27 Biostar, Inc. Devices and methods for detection of an analyte based upon light interference
US5824799A (en) 1993-09-24 1998-10-20 Biosite Diagnostics Incorporated Hybrid phthalocyanine derivatives and their uses
US5647124A (en) 1994-04-25 1997-07-15 Texas Instruments Incorporated Method of attachment of a semiconductor slotted lead to a substrate
CA2154117C (en) 1994-08-09 1999-11-16 Tatsuhiko Ikeda Apparatus for inhibiting glycolysis in blood samples
US5792294A (en) 1995-11-16 1998-08-11 Otis Elevator Company Method of replacing sheave liner
US6113855A (en) 1996-11-15 2000-09-05 Biosite Diagnostics, Inc. Devices comprising multiple capillarity inducing surfaces
US20030165831A1 (en) * 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2006527190A (ja) 2003-04-17 2006-11-30 サイファージェン バイオシステムズ インコーポレイテッド ナトリウム利尿ペプチドに関連したポリペプチド、並びにこれらの同定および使用法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104878077A (zh) * 2014-02-28 2015-09-02 谭巍 PCA3 mRNA/ACPP mRNA RT-PCR检测引物及检测试剂盒

Also Published As

Publication number Publication date
WO2007142540A1 (en) 2007-12-13
EP2029745A4 (en) 2009-12-16
EP2029745B1 (en) 2011-10-12
AU2007255981A1 (en) 2007-12-13
US20110287010A1 (en) 2011-11-24
CA2687997A1 (en) 2007-12-13
ATE528411T1 (de) 2011-10-15
EP2029745A1 (en) 2009-03-04
JP2009539370A (ja) 2009-11-19

Similar Documents

Publication Publication Date Title
JP3949165B2 (ja) Dna配列及びエンコードされた乳房に特異的な乳癌たんぱく質
US7736853B2 (en) Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
KR101828290B1 (ko) 자궁내막암 마커
US20030235820A1 (en) Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
CN101535480A (zh) 诊断方法和标记物
Chaib et al. Activated in prostate cancer: a PDZ domain-containing protein highly expressed in human primary prostate tumors
WO2003063773A2 (en) Differentially-regulated prostate cancer genes
Manne et al. Altered subcellular localization of suppressin, a novel inhibitor of cell-cycle entry, is an independent prognostic factor in colorectal adenocarcinomas
JP2010063464A (ja) 癌における新規な組成物および方法
WO2005015236A2 (en) A method for predicting the progression of adenocarcinoma
US6617104B2 (en) Predisposition to breast cancer by mutations at the ataxia-telangiectasia genetic locus
WO2004009836A2 (en) Pr/set-domain containing nucleic acids, polypeptides, antibodies and methods of use
CA2510774A1 (en) Amplified cancer target genes useful in diagnosis and therapeutic screening
US7883896B2 (en) Marker molecules associated with lung tumors
JP5688497B2 (ja) 肺腺癌患者の術後予後を予測するための方法及び組成物
CN101479391A (zh) 用于检测cripto-3的组合物及方法
JP2006519589A5 (enExample)
KR101683961B1 (ko) 방광암 재발 진단 마커
CA2491420A1 (en) Rb1 gene induced protein (rb1cc1) and gene
KR101093508B1 (ko) 대장암 진단용 조성물 및 그 용도
US20040072192A1 (en) Cancer-linked genes as targets for chemotherapy
US7189551B2 (en) Human RPS6KA6-related gene variant associated with lung cancers
US9200262B2 (en) Method for the diagnosis of the presence of an ovarian cancer
EP1797196B1 (en) Detection of breast cancer
KR20110036558A (ko) 대장암 진단용 조성물 및 그 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20090916